A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drug
Although this study enrolled a relatively small cohort of cirrhotic patients with hyperammonemia, RQZ demonstrated an excellent safety profile as an intestinally restricted agent and showed promising potential for lowering blood ammonia and treating hepatic encephalopathy.
Authors
- Niu Jq
- Jingrui Liu (ORCID: https://orcid.org/0009-0004-2663-6485)
- Guozhu Geng
- Zhenkun Ma (ORCID: https://orcid.org/0009-0007-2300-6308)
- Changlin Ai
- Y. X. Ding
- Jing Chen
- Mengdi Lu
- Jia Xu
- Hong Zhang
- Chunhua Shi
- Yue Hu
- Xiaojiao Li
Institutions
- Jilin University (CN)
- First Hospital of Jilin University (CN)
- Tenneco (United States) (US)
Publication Details
- Journal
- Expert Opinion on Investigational Drugs
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1080/13543784.2026.2619604
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00